Creo Medical Group (LON:CREO) Stock Price Up 14.7% – Should You Buy?

Creo Medical Group PLC (LON:CREO) was up 14.7% on Friday . The company traded as high as GBX 20 ($0.25) and last traded at GBX 19.50 ($0.25). Approximately 1,732,157 shares changed hands during mid-day trading, an increase of 139% from the average daily volume of 723,984 shares. The stock had previously closed at GBX 17 ($0.21).

Creo Medical Group Stock Performance

The company has a 50-day moving average of GBX 17.83 and a 200-day moving average of GBX 25.98. The firm has a market capitalization of £70.55 million, a price-to-earnings ratio of -325.00 and a beta of 0.86. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96.

Insider Transactions at Creo Medical Group

In other news, insider Kevin Crofton purchased 1,179,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average price of GBX 17 ($0.21) per share, with a total value of £200,430 ($251,891.42). Also, insider Richard John Rees acquired 98,000 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was purchased at an average price of GBX 20 ($0.25) per share, for a total transaction of £19,600 ($24,632.40). Over the last ninety days, insiders have purchased 4,193,666 shares of company stock valued at $92,002,984. 22.43% of the stock is owned by insiders.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.